Immucell Stock Odds of Future Stock Price Finishing Under 0.04
| ICCC Stock | USD 3.69 0.03 0.82% |
ImmuCell |
ImmuCell Target Price Odds to finish below 0.04
The tendency of ImmuCell Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 0.04 or more in 90 days |
| 3.69 | 90 days | 0.04 | near 1 |
Based on a normal probability distribution, the odds of ImmuCell to drop to $ 0.04 or more in 90 days from now is near 1 (This ImmuCell probability density function shows the probability of ImmuCell Stock to fall within a particular range of prices over 90 days) . Probability of ImmuCell price to stay between $ 0.04 and its current price of $3.69 at the end of the 90-day period is about 64.04 .
Given the investment horizon of 90 days ImmuCell has a beta of -0.66. This usually indicates as returns on the benchmark increase, returns on holding ImmuCell are expected to decrease at a much lower rate. During a bear market, however, ImmuCell is likely to outperform the market. Additionally ImmuCell has an alpha of 0.1421, implying that it can generate a 0.14 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). ImmuCell Price Density |
| Price |
Predictive Modules for ImmuCell
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ImmuCell. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ImmuCell's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
ImmuCell Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. ImmuCell is not an exception. The market had few large corrections towards the ImmuCell's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold ImmuCell, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of ImmuCell within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.14 | |
β | Beta against Dow Jones | -0.66 | |
σ | Overall volatility | 0.11 | |
Ir | Information ratio | -0.02 |
ImmuCell Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ImmuCell for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for ImmuCell can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 17.47 M. Net Loss for the year was (5.77 M) with profit before overhead, payroll, taxes, and interest of 7.65 B. | |
| ImmuCell currently holds about 11.04 M in cash with (4.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.43. | |
| ImmuCell has a frail financial position based on the latest SEC disclosures | |
| Roughly 40.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: ImmuCell Q3 Earnings Decline YY, Sales Grow Amid Margin Challenges - MSN |
ImmuCell Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of ImmuCell Stock often depends not only on the future outlook of the current and potential ImmuCell's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ImmuCell's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 7.7 M | |
| Cash And Short Term Investments | 978.7 K |
ImmuCell Technical Analysis
ImmuCell's future price can be derived by breaking down and analyzing its technical indicators over time. ImmuCell Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of ImmuCell. In general, you should focus on analyzing ImmuCell Stock price patterns and their correlations with different microeconomic environments and drivers.
ImmuCell Predictive Forecast Models
ImmuCell's time-series forecasting models is one of many ImmuCell's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary ImmuCell's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about ImmuCell
Checking the ongoing alerts about ImmuCell for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for ImmuCell help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| The company reported the previous year's revenue of 17.47 M. Net Loss for the year was (5.77 M) with profit before overhead, payroll, taxes, and interest of 7.65 B. | |
| ImmuCell currently holds about 11.04 M in cash with (4.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.43. | |
| ImmuCell has a frail financial position based on the latest SEC disclosures | |
| Roughly 40.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: ImmuCell Q3 Earnings Decline YY, Sales Grow Amid Margin Challenges - MSN |
Check out ImmuCell Backtesting, ImmuCell Valuation, ImmuCell Correlation, ImmuCell Hype Analysis, ImmuCell Volatility, ImmuCell History as well as ImmuCell Performance. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.63) | Earnings Share (0.49) | Revenue Per Share 2.991 | Quarterly Revenue Growth 0.549 | Return On Assets (0.05) |
The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.